The Company’s Consolidated Unaudited Interim Financial Statements as of September 30, 2021, and for the three months then ended - Form 6-K

Purple Biotech Ltd.

Consolidated Unaudited Statements of Financial Position as of:

		September 30			December 31
		2021			2020
		USD thousands			USD thousands
Assets
Cash and cash equivalents			9,117				11,247
Short term deposits			36,447				46,558
Trade receivables			500				500
Other current assets			1,133				977
Total current assets			47,197				59,282
Non-current assets
Right to use assets			658				790
Fixed assets, net			273				178
Long term deposits			5,018				3,071
Intangible assets			20,482				20,482
Total assets			73,628				83,803
Liabilities
Lease liability - short term			199				207
Accounts payable			2,083				1,198
Other payables			1,144				1,693
Total current liabilities			3,426				3,098
Non-current liabilities
Lease liability			563				688
Post-employment benefit liabilities			265				265
Total non-current liabilities			828				953
Equity
Share capital, no par value			-				-
Share premium			122,214				118,909
Receipts on account of warrants			28,015				29,984
Capital reserve for share-based payments			9,764				8,115
Capital reserve from transactions with related parties			761				761
Capital reserve from transactions with non-controlling
interest			(859	)			(859	)
Accumulated loss			(90,834	)			(77,521	)
Equity attributable to owners of the Company			69,061				79,389
Non-controlling interests			313				363
Total equity			69,374				79,752
Total liabilities and equity			73,628				83,803

Purple Biotech Ltd.

Consolidated Unaudited Statement of Operations for the period ended

		3 months ended in September			9 months ended September 30
		2021			2021
		USD thousands			USD thousands
Research and development expenses			1,793				8,884
Sales, general and administrative expenses			1,403				4,599
Total operating expenses			3,196				13,483
Operating loss			3,196				13,483
Expenses (income) on account of warrants							-
Finance expenses			21				143
Finance income			(68	)			(264	)
Finance expenses (income), net			(47	)			(121	)
Loss for the period			3,149				13,362
Loss attributable to:
Owners of the Company			3,137				13,313
Non-controlling interests			12				50
			3,149				13,363
Loss per share data
Basic and diluted loss per ADS - USD			0.20				0.76
Number of shares used in calculating basic and diluted loss per ADS			17,512,257				17,512,257

Reconciliation of Adjusted Operating Loss

		3 months ended in September			9 months ended September 30
		2021			2021
		USD thousands			USD thousands
Operating loss for the period			3,196				13,483
Less ESOP expenses			(392	)			(1,777	)
			2,804				11,706